Prediction of Long-Term Survival by Three Risk Assessment Models in Patients with Pulmonary Arterial Hypertension: A SPAHR Analysis
Purpose: Multicomponent clinical improvement (MCI) is a novel endpoint for predicting survival in patients with pulmonary arterial hypertension (PAH) included in the sotatercept clinical program. We investigated the prognostic value of MCI, ESC/ERS 4-strata risk (4SR) assessment, and the French risk stratification score (FRS) for predicting survival in a real-world cohort of PAH patients.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , T. Thakur, T. Weiss, E. Bj örklund, J. Papageorgiou, G. Radegran, S. Soderberg, H. Wahlander, D. Lautsch, B. Kjellström Source Type: research
More News: Cardiology | France Health | Heart | Heart Transplant | Hypertension | Lung Transplant | Transplant Surgery | Transplants